Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel A Funt

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk DiseaseJack P Gleeson, Andrea Knezevic, Maria Bromberg, et al.
Frontiers in Genetics|April 10, 2023
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapyAnnie Borch, Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, et al.
Investigational New Drugs|May 25, 2021
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumorsRyan Ashkar, Darren R Feldman, Nabil Adra, et al.
Annals of Surgery|January 25, 2020
Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell TumorsRaul Caso, Gregory D Jones, Manjit S Bains, et al.
The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.
Breast Cancer Research and Treatment|July 3, 2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancerDiana G Wang, Dulce M Barrios, Victoria S Blinder, et al.
JCO Oncology Practice|June 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer ResearchMichal Sternschuss, Michael Lattanzi, Emily Vertosick, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
Journal of Neuro-Oncology|June 17, 2026
Stereotactic radiosurgery and multimodal integration approaches for germ cell tumor brain relapseChengcheng Gui, Samuel A Funt, Lillian A Boe, et al.
The Journal of Clinical Investigation|February 10, 2015
Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammationMohamed A Saleh, William G McMaster, Jing Wu, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk DiseaseJack P Gleeson, Andrea Knezevic, Maria Bromberg, et al.
Frontiers in Genetics|April 10, 2023
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapyAnnie Borch, Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, et al.
Investigational New Drugs|May 25, 2021
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumorsRyan Ashkar, Darren R Feldman, Nabil Adra, et al.
Annals of Surgery|January 25, 2020
Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell TumorsRaul Caso, Gregory D Jones, Manjit S Bains, et al.
The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.
Breast Cancer Research and Treatment|July 3, 2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancerDiana G Wang, Dulce M Barrios, Victoria S Blinder, et al.
JCO Oncology Practice|June 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer ResearchMichal Sternschuss, Michael Lattanzi, Emily Vertosick, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
Journal of Neuro-Oncology|June 17, 2026
Stereotactic radiosurgery and multimodal integration approaches for germ cell tumor brain relapseChengcheng Gui, Samuel A Funt, Lillian A Boe, et al.
The Journal of Clinical Investigation|February 10, 2015
Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammationMohamed A Saleh, William G McMaster, Jing Wu, et al.
Pageof 8